Zealand Pharma — Januar 2024
-
Det var et hurtigt comeback til 380+, efter et lille dyk ned omkring 340….Køberne står åbenbart klar til at samle op, når der kommer lidt gevinsthjemtagning.
-
Der blev sat ATH intraday d 28 dec i 386, og den nærmer vi os igen
-
Måske hype på baggund af opkøbs rygter i et andet biotek selskab (andet segment,men biotek)https://www.euroinvestor.dk/nyheder/efter-vilde-rygter-aktie-stiger-over-100-pct
-
Pharmaceutical and life sciences: US Deals 2024 outlook:
Pharmaceutical and life sciences: US Deals 2026 outlook: M&A Trends
Explore the 2026 US pharmaceutical and life sciences M&A outlook, from precision-led biopharma deals and loss-of-exclusivity pressures to cross-border licensing and alternative capital structures.
PwC (www.pwc.com)
(pwc)
Mere ned i indkøbsposen
-
Johnson & Johnson to acquire Ambrx in $2 billion deal
-
tak @exitnu
-
Jeg tror ikke at Bloomberg artikelen skal undervurderes i betydning for kursen.
-
Det er imponerende re-bound for ZP.
-
helt ok @exitnu - dejlig dag her på chatten og i depotet
-
Exitnu….Det kan være at sækken bliver lukket af sig selv
Ved opkøbstilbud Drømmerier, men vel ikke HELT usandsynligt -
Hvis tilbuddet er højt nok, så kan Adam signalere mange ting
Money rules”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind